Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

Sieghart, Wolfgang; Pinter, Matthias; Reisegger, Michael; Müller, Christian; Ba‐Ssalamah, Ahmed; Lämmer, Johannes; Peck‐Radosavljevic, Markus

doi:10.1007/s00330-011-2368-z

Cited by 39 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the positive outcomes reported with the combined therapy, a clinical trial that enrolled a small number of patients was stopped prematurely due to adverse events (AE) and safety concerns with the combination therapy of high-dose doxorubicinbased TACE regimen and sorafenib [31] .…”

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

Muhammad¹

2013

WJH

View full text Add to dashboard Cite

AIM:To compare the overall survival (OS) and progression-free survival (PFS) with associated adverse events (AE) in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) + sorafenib vs TACE alone. METHODS:In this retrospective cohort study we collected data on all consecutive patients with a diagnosis of unresectable HCC between 2007 and 2011 who had been treated with TACE + sorafenib or TACE alone. We hypothesized that the combination therapy is superior to TACE alone in improving the survival in these patients. Data extracted included patient's demographics, etiology of liver disease, histology of HCC, stage of liver disease with respect to model of end stage liver disease score and Child-Turcotte-Pugh (CTP) classification and Barcelona Clinic Liver Cancer (BCLC) staging for HCC. Computed tomography scan findings, alpha fetoprotein levels, number of treatments and related AE were also recorded and analyzed. RESULTS:Of the 43 patients who met inclusion criteria, 13 were treated with TACE + sorafenib and 30 with TACE alone. There was no significant difference in median survival: 20.6 mo (95%CI: 13.4-38.4) for the TACE + sorafenib and 18.3 mo (95%CI: 11.8-32.9) for the TACE alone (P = 0.72). There were also no statistically significant differences between groups in OS (HR = 0.82, 95%CI: 0.38-1.77; P = 0.61), PFS (HR = 0.93, 95%CI: 0.45-1.89; P = 0.83), and treatmentrelated toxicities (P = 0.554). CTP classification and BCLC staging for HCC were statistically significant (P = 0.001, P = 0.04 respectively) in predicting the survival in patients with HCC. The common AE observed were abdominal pain, nausea, vomiting and mild elevation of liver enzymes. CONCLUSION:Combination therapy with TACE + sorafenib is safe and equally effective as TACE alone in patients with unresectable HCC. CTP classification and BCLC staging were the significant predictors of survival. Future trials with large number of patients are needed to further validate this observation.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

Muhammad¹

2013

WJH

View full text Add to dashboard Cite

show abstract

“…At 6 months, seven patients presented complete (two) or partial (five) responses, and one had stable disease. Median overall survival was 10.6 months (95% CI: 5.2 -16 months) [15].…”

Section: Discussionmentioning

confidence: 99%

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

Romeiro¹,

Sigahi²,

Alvarez³

et al. 2015

JCT

View full text Add to dashboard Cite

show abstract

“…However, the addition of sorafenib failed to prolong TTP (5.4 months vs. 3.7 months; HR = 0.87; P = 0.252) [58]. Subsequently, a number of phase II trials evaluating the efficacy and safety of conventional TACE or TACE with doxorubicin-eluting beads (DEB) with concurrent sorafenib (which started within 14 days before or after TACE was carried out) revealed inconsistent results [59,60,61,62,63,64]. The diversity of study designs created confounding factors including primary endpoints, patient populations, TACE procedures, timing of randomization, and drug administration may account for these conflicting results [69].…”

Section: Clinical Trials Of Molecular Targeted Therapy In Combinationmentioning

confidence: 99%

“…Data from clinical trials on a variety of molecular targeted therapies in combination with locoregional therapy are shown in table 2[58,59,60,61,62,63,64,65,66,67,68]. …”

Section: Clinical Trials Of Molecular Targeted Therapy In Combinationmentioning

confidence: 99%

Clinical Trials in Hepatocellular Carcinoma: An Update

et al. 2013

View full text Add to dashboard Cite

The success of sorafenib has spurred an explosive increase of clinical trials testing novel molecular targets and other agents in the treatment of hepatocellular carcinoma (HCC). The paradigm of the studies has been characterized by three noticeable changes. First, the molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for advanced HCC treatment. Agents targeting EGFR, FGFR, PI3K/Akt/mTOR, TGF-β, c-Met, MEK, IGF signaling, and histone deacetylase have been actively explored. Second, the target indication has shifted from advanced stage to early or intermediate stages of disease. The feasibility of combining locoregional therapies and targeted agents, and the use of novel agents after curative treatments are currently under active investigation. Finally, the therapeutic strategy has shifted from monotherapy to combination targeted therapy. We aim to provide a comprehensive overview of newly disclosed and ongoing clinical trials for the treatment of HCC.

show abstract

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

Cited by 39 publications

References 39 publications

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

Sorafenib after Arterial Chemoembolization in Child-Pugh A and B Cirrhotic Patients with Intermediate Hepatocellular Carcinoma: A Retrospective Analysis

Clinical Trials in Hepatocellular Carcinoma: An Update

Contact Info

Product

Resources

About